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ALS is an adult-onset neurodegenerative disorder characterized 
by rapidly progressive paralysis and death from respiratory failure, 
typically within 2 to 3 years of symptom onset1. There are no effec-
tive cures for ALS, though the benzothiazole riluzole slows the rate 
of progression and prolongs survival by three months1. As in other 
neurodegenerative diseases, ~10% of ALS is classified as familial, 
whereas the remaining 90% of cases are considered sporadic, as they 
appear to occur randomly throughout the community1.
Unraveling the genetic etiology of ALS has provided fundamental 
insights into the cellular mechanisms underlying neuron degenera-
tion, as well as facilitating disease modeling and the design and testing 
of targeted therapeutics; thus, it is not surprising that considerable 
resources have been devoted to finding pathogenic mutations. SOD1 
mutations were found to cause familial ALS in 1993 (ref. 2), but there 
was a long hiatus until the discovery of the next ALS gene, TARDBP, 
in 2008 (ref. 3). Today, the pace of gene discovery has greatly acceler-
ated, fuelled in large part by advances in sequencing and genotyping 
technology. In the last 3 years alone, six new ALS genes have been 
discovered4–10, and we now know the genetic etiology of two-thirds 
of familial cases and about 11% of sporadic ALS cases.
This Review will focus on recent genetic discoveries in ALS and 
how genetics is changing our understanding of this fatal, mysterious 
disorder. In the first section, we examine the main genes implicated 
in the pathogenesis of ALS. We will then discuss attempts to find 
genetic variants underlying sporadic ALS using genome-wide associa-
tion studies (GWAS). Finally, we will describe emerging concepts in 
ALS genetics and where we ultimately think the road ahead leads.
Familial ALS genes
To provide a historical context, we present the main ALS genes in 
the order in which they were discovered (Fig. 1 and Table 1).
Superoxide dismutase 1 (SOD1).  The identification of dominant 
missense mutations in SOD1 20 years ago represented the first 
demonstration that linkage analysis could successfully pinpoint 
the underlying genetic cause of a rare neurodegenerative disease2. 
Although over a hundred SOD1 mutations have been reported, 
 reliable genetic evidence of pathogenicity exists for only a portion 
of these11. Nevertheless, population-based studies show that muta-
tions in this gene account for ~12% of familial cases and ~1% of 
sporadic cases12.
Considerable phenotypic heterogeneity occurs across the various 
SOD1 mutations. For example, the A4V mutation, which is the most 
frequent variant in North America, gives rise to an aggressive form of 
ALS that typically leads to death within a year after symptom onset13. 
In contrast, the homozygous D90A mutation in the same gene is asso-
ciated with an indolent course, with patients developing respiratory 
failure only after 10 years of illness14. Cognitive impairment is not 
a prominent feature of SOD1 disease, though patients with D90A 
manifest cognitive issues at the later stages of the disease, perhaps 
reflecting their protracted survival and the corresponding longer time 
to manifest disease spreading to nonmotor prefrontal areas15.
The discovery that SOD1 mutations cause ALS led directly to the 
development of the SOD1 transgenic mouse. Though important in 
elucidating the cellular mechanisms by which disruption of this 
gene predispose to motor neuron degeneration16, the use of this 
model to select agents for human trials has been increasingly called 
into question17. Indeed, the pathology of human SOD1 ALS is now 
thought to be distinct from that of all other types of ALS, in that 
it lacks the TDP-43 and/or FUS pathology present in nearly every 
other instance18. In recognition of this fact, there have been recent 
efforts to selectively treat patients carrying mutated SOD1 using 
antisense oligonucleotide therapy designed to knock down expres-
sion of the gene19.
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State of play in amyotrophic lateral 
sclerosis genetics
Alan E Renton1, Adriano Chiò2 & Bryan J Traynor1,3
Considerable progress has been made in unraveling the genetic etiology of amyotrophic lateral sclerosis (ALS), the most common 
form of adult-onset motor neuron disease and the third most common neurodegenerative disease overall. Here we review genes 
implicated in the pathogenesis of motor neuron degeneration and how this new information is changing the way we think about 
this fatal disorder. Specifically, we summarize current literature of the major genes underlying ALS, SOD1, TARDBP, FUS,  
OPTN, VCP, UBQLN2, C9ORF72 and PFN1, and evaluate the information being gleaned from genome-wide association studies.  
We also outline emerging themes in ALS research, such as next-generation sequencing approaches to identify de novo mutations, 
the genetic convergence of familial and sporadic ALS, the proposed oligogenic basis for the disease, and how each new genetic 
discovery is broadening the phenotype associated with the clinical entity we know as ALS.
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TAR DNA-binding protein (TARDBP). A landmark event in our 
understanding of ALS pathogenesis was the discovery that the TDP-
43 protein is a major component of the ubiquitin-positive neuronal 
inclusions that are the pathological hallmark of both ALS and fronto-
temporal dementia (FTD)20. This seminal observation provided vital 
evidence that these distinct conditions constitute a disease spectrum, 
rather than being discrete clinical entities. It also directly led to the 
discovery of mutations in TARDBP (which encodes TDP-43) in 
autosomal dominant ALS and FTD families3,21. These pathogenic 
variants were mostly located in the C terminus, which is involved in 
ribonucleoprotein binding and splicing.
Mutations in TARDBP account for ~4% of familial ALS cases and 
a smaller percentage of sporadic ALS cases22. Although TARDBP 
mutations are found in ALS families across the globe, some regional 
variability does exist. For example, the A382T mutation of the pro-
tein is particularly frequent in Sardinia, reflecting the conserved 
nature of that island population combined with a historical founder 
effect23. Nevertheless, the overall mutational frequency of the gene 
remains much lower than the occurrence of TDP-43 neuropathologi-
cal changes observed in autopsies.
The discovery of the central role of TDP-43 in ALS pathogenesis 
has highlighted the importance of RNA processing. Additional sup-
port for this hypothesis comes from the discovery of FUS, another 
RNA-binding protein (see below). Considerable efforts have been 
made to understand exactly how mutations in these genes dis-
rupt RNA transcription and to identify RNA species modified by 
both proteins24.
Fused in sarcoma (FUS). Shortly after the cloning of TARDBP, mis-
sense mutations of FUS were identified as the cause of chromosome 
16p–linked familial ALS25,26. Although this gene accounts for a small 
percentage of familial cases (~4%), its discovery caused consider-
able excitement in the field because the protein shares functional 
homology with TDP-43. Furthermore, FUS mutations cluster in the 
RNA-binding domain at the C terminus of the protein, as seen with 
TARDBP. These observations reinforced the importance of abnormal 
RNA metabolism in motor neuron degeneration.
Neuropathological analyses of patients carrying FUS mutations 
have yielded important insights into the disease. Though some 
debate remains, it would appear that FUS cases are characterized by 
FUS-immunoreactive cytoplasmic inclusions with a striking absence 
of the ubiquitin-positive and TDP-43-positive aggregates that distin-
guish most ALS cases25,26. One possible explanation for this finding is 
that FUS acts downstream of TDP-43 in the same pathway27.
Optineurin (OPTN). OPTN mutations were initially described as 
a cause of autosomal recessive ALS in Japanese families in 2010 
(ref. 9). Since then, it has become clear that heterozygous mutations 
in this gene rarely cause familial ALS among people of European 
ancestry22. This may reflect different genetic etiologies underlying 
motor neuron degeneration across major ethnic groups. Indeed, auto-
somal recessive ALS may be more common in Japan compared to 
Europe and North America.
Nevertheless, the phenotypic pleiotropy associated with OPTN is 
intriguing. Mutations in this gene have long been described as a cause 
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Figure 1 Timeline of gene discoveries in familial and sporadic ALS. Values represent the proportion of ALS explained by each gene in populations of 
European ancestry. References are provided in the main text.
Table 1 Genes known to carry ALS-causing mutations
Gene Location Inheritance
Percentage explained Putative protein  
functionFamilial ALS Sporadic ALS
TARDBP 1p36 AD 4 1 RNA metabolism
SQSTM1 5q35 AD 1 <1 Ubiquitination; 
autophagy
C9ORF72 9p21 AD 40 7 DENN protein
VCP 9p13 AD 1 1 Proteasome; vesicle 
trafficking
OPTN 10p13 AR and AD <1 <1 Vesicle trafficking
FUS 16p11 AD and AR 4 1 RNA metabolism
PFN1 17p13 AD <1 <1 Cytoskeletal 
dynamics
SOD1 21q22 AD and AR 12 1–2 Superoxide 
metabolism
UBQLN2 Xp11 XD <1 <1 Proteasome
Values represent the percentage of ALS explained by each gene in populations of 
European ancestry. References are provided in the main text. AD, autosomal dominant; 
AR, autosomal recessive; XD, X-linked dominant; DENN, differentially expressed in 
normal and neoplasia.
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of primary open angle glaucoma28, and more recently the OPTN locus 
was implicated in a GWAS of Paget’s disease of bone29. Along with 
VCP and SQSTM1 (see below), this provides information supporting 
a clinical overlap between Paget’s disease and ALS. Although OPTN 
regulates diverse cellular processes, including membrane trafficking, 
protein secretion, cell division and host defense against pathogens30, 
it remains to be determined exactly how mutations in this gene may 
give rise to such a wide range of clinical phenotypes.
Valosin-containing protein (VCP). Also in 2010, we reported that 
mutations in VCP are responsible for 1–2% of familial ALS cases5, 
a finding that was subsequently confirmed by other studies31,32. This 
was the first time that whole-exome sequencing had been successfully 
applied to a major neurodegenerative disorder. The power of this 
new technology is based on its use of the massively parallel sequenc-
ing capabilities of next-generation sequencing platforms to rapidly 
identify rare variants in the ~2% of the genome that encodes proteins. 
Moreover, whole-exome sequencing is a realistic strategy for detecting 
pathogenic variants in small families where linkage analysis would not 
be possible due to a shortage of DNA samples from affected individu-
als. This is particularly true in ALS, where the rapidly fatal nature of 
the syndrome makes it challenging to collect families of sufficient size 
to perform linkage analysis.
Mutations in VCP were already known to underlie an unusual clini-
cal syndrome characterized by FTD, inclusion body myopathy and 
Paget’s disease of the bone (IBMPFD)33. Thus, the discovery of muta-
tions in the same gene resulting in an ALS phenotype represented 
another step in our unraveling of the genetic links between motor 
neuron degeneration and FTD. The coexistence of inclusion body 
myopathy in these patients was similarly interesting because it dem-
onstrated that mutations in a single gene could result in pathology on 
both sides of the neuromuscular junction. This has given rise to the 
concept of multisystem proteinopathy, in which multiple tissues are 
affected34. Recent work has convincingly demonstrated that muta-
tions in VCP cause mitochondrial uncoupling leading to a significant 
reduction of cellular ATP production, perhaps explaining disparate 
effects across multiple tissues35.
Ubiquilin 2 (UBQLN2). Missense mutations in UBQLN2, located on 
the short arm of chromosome X, were initially identified in appar-
ently autosomal dominant ALS pedigrees lacking male-to-male 
transmission4. Although isolated ALS was the predominant pheno-
type associated with mutations in this gene, occasional patients had 
concomitant symptoms of FTD. It is already evident that UBQLN2 
mutations are not a common cause of familial ALS36. Nevertheless, 
ubiquilin 2 pathology has been observed in ALS patients who do 
not carry mutations in the gene, suggesting that this protein, which 
regulates proteasome degradation of ubiquitinated proteins, may be 
an important component of the final common pathway mediating 
motor neuron degeneration4.
Hexanucleotide repeat expansion in C9ORF72. We and others 
recently reported that a massive hexanucleotide repeat expansion in 
C9ORF72 is the cause of chromosome 9p21–linked ALS and FTD7,8. 
Long sought after, cloning of this locus has reinvigorated the ALS 
and FTD research field for a variety of reasons. First, the pathogenic 
expansion accounts for a remarkable percentage of both familial ALS 
(~40%) and familial FTD (~25%) and genetically explains the majority 
of the overlap of these two disparate clinical syndromes37. Second, 
the repeat expansion has been found to account ~7% of apparently 
sporadic ALS cases in people of European ancestry, marking the first 
time that a genetic etiology has been identified for more than just 
the occasional sporadic case. Third, this is the first time that a large 
intronic repeat expansion has been implicated in ALS. Given that 
repeat expansions are known to disrupt RNA metabolism in other 
neurodegenerative diseases, it again points toward the importance 
of this pathway in the maintenance of motor and frontal cortex 
neurons. Finally, there is a real chance that gene therapy based on 
antisense oligonucleotides will be effective in slowing progression in 
ALS patients who carry the expansion (approximately one in ten ALS 
cases in European-ancestry populations). There are already concerted 
efforts to bring such a therapy forward into human trials.
Several important questions concerning C9ORF72 remain unan-
swered. For example, what is the full range of phenotypes associated 
with this mutation? The expansion may underlie a small portion of 
clinical Alzheimer’s disease and Parkinson’s disease cases38,39, but 
what is its role in neuropsychiatric disorders? A corollary question is 
why some patients present with motor dysfunction and others with 
frontal lobe impairment. Although there are anecdotal reports of 
anticipation (the onset of symptoms at an earlier age in subsequent 
generations) in C9ORF72 families40, is this a robust finding? If so, is 
the repeat expansion itself unstable, and what role does such instabil-
ity play in determining disease phenotype and severity? Early data 
point to considerable instability of the expansion both across families 
and within individuals (somatic mutation)41. Is the GGGGCC repeat 
pure or interrupted, and how might that influence phenotype? What 
genomic and cellular substrates underlie the variable penetrance 
observed among individuals carrying the expansion?37 Methylation 
has been shown to be an important determinant of age of symptom 
onset in other repeat-expansion diseases, and there are data to suggest 
that this may be relevant in C9ORF72 (ref. 42).
Finally, and perhaps most pressing for the development of gene 
therapies targeting the locus, how does the repeat expansion give 
rise to disease? RNA foci are observed in fibroblasts derived from 
C9ORF72 patients, implicating disruption of RNA metabolism 
through sequestration of RNA-binding proteins and other RNA 
species8. However, a more direct role for C9ORF72 protein in the 
nucleus has not been excluded, suggesting that haploinsufficiency 
may also be relevant. C9ORF72 hexanucleotide repeats form highly 
stable RNA G-quadruplexes, which may influence telomere stability 
and RNA transcription, splicing, translation and transport43. More 
recently, repeat-associated non-ATG (RAN) protein translation has 
been observed44. Although it is not known whether the inclusions 
generated from such aberrant translation are involved in neuronal 
cell death, this process has been directly implicated in cellular toxicity 
associated with fragile X tremor ataxia, a different noncoding repeat 
expansion disease45.
Sequestosome 1 (SQSTM1). SQSTM1 encodes p62, a major patho-
logic protein deposited in neurodegeneration. P62 regulates ubiquitin 
binding and activation of nuclear factor kappa-B signaling. Mutations 
in this gene are known to cause Paget’s disease of bone46. A candidate 
gene screening approach identified missense and deletion variants in 
~1% of ALS cases10. Follow-up studies have shown a similar muta-
tional frequency rate, though, as of yet, segregation of variants with 
disease within a large family has not been reported47,48.
Profilin 1 (PFN1). In late 2012 Wu et al. reported that missense muta-
tions in PFN1 segregated with disease in several large ALS kindreds6. 
Although this gene has only been recently described as pathogenic 
mutational screening of sizeable ALS and FTD cohorts from sev-
eral populations already demonstrate that PFN1 mutations are not 
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a prominent cause of neurodegeneration49. 
Nevertheless, this discovery implicates a new 
cellular mechanism in the pathogenesis of 
ALS, namely disruption of the cytoskeletal 
architecture of the neuron.
Other genes. Mutations in several other genes 
have been reported as rare causes of ALS or 
ALS-like syndromes (Table 2). In the case of 
ALS2, the associated phenotype is more con-
sistent with slowly progressive, juvenile-onset, 
hereditary spastic paraplegia, rather than 
adult-onset ALS50,51. Similarly, mutations in 
SETX are more typically associated with an 
ataxia phenotype, rather than ALS52,53.
In other cases, the genetic evidence sup-
porting a role as an ALS gene is not fully con-
vincing. For example, there have been no reports of FIG4 or DAO 
mutations as a cause of ALS since their initial publications54,55. By the 
same token, only a single pedigree showing convincing segregation 
of ALS with a DCTN1 mutation has been described, and mutations 
in this gene are now more commonly linked to Parkinson’s disease 
with hypoventilation and depression (Perry syndrome)56,57. Apart 
from the Brazilian ALS families in which the original VAPB muta-
tions were reported, there have been no additional publications of 
segregating mutations in this gene58,59. Though there is good evidence 
for a private mutation in CHMP2B in a large Danish family with 
FTD, there is only minimal data to support its involvement in ALS 
pathogenesis60–62. The role of the candidate gene ANG, nominated 
on the basis of its angiogenic properties, remains ambiguous for both 
familial and sporadic ALS22,63–65.
Genome-wide association studies of ALS
Susceptibility loci. There have been 14 GWAS published in ALS, 
and they have already made significant contributions to our under-
standing of ALS genetics66–79. Our own GWAS of ALS in Finland 
was the first to identify a significant association peak on the short 
arm of chromosome 9 in this founder population75. This remains the 
most consistent signal yet observed73,76,78 and was instrumental in 
the cloning of the C9ORF72 locus, as the dense nature of the single 
nucleotide polymorphisms (SNPs) on the genotyping platform 
narrowed the scope of the search.
A variety of other risk loci have been nominated on the basis of 
ALS GWAS. Many of them, such as FGGY, ITPR2 and DPP6 have 
not stood up to replication in large cohorts71,77,80. Others, such as 
UNC13A, appear more robust, although true replication of this locus 
in an independent cohort is still pending78,81. More recently, a GWAS 
of ALS in people of non-European ancestry identified new loci at 
1q32 and 22p11 as potentially relevant to ALS pathogenesis, though 
the discovery cohort was small (n = 506) for an outbred population 
such as the Han Chinese79. The field eagerly anticipates independent 
replication of these findings in larger case-control cohorts.
ALS genetic research has been largely focused on populations of 
European ancestry, and attention has only recently shifted to other 
ethnicities. Early indications are that the genetic architecture of ALS 
is distinct in other regions of the world. For example, the frequency 
of the C9ORF72 repeat expansion is far lower among Japanese than 
among Europeans37, whereas the inverse pattern is observed for 
OPTN mutations. Future genetic discoveries in non-European popu-
lations will likely unravel the diverse means by which motor neuron 
degeneration can occur.
Age at symptom onset and survival phenotypes. In addition to 
searching for susceptibility loci, there have been genome-wide efforts 
to identify genetic variants influencing ALS phenotype. For example, 
genetic variation in the KIFAP3 and EPHA4 loci has been reported to 
significantly influence survival among ALS patients72,82, and a large 
meta-analysis of ALS GWAS recently reported that age of onset is 
modulated by a locus on the short arm of chromosome 1 (ref. 78). 
The motivation for these efforts is based on the notion that such loci 
represent final common pathways involved in the death of motor 
neurons and that the cellular mechanisms that drive neurodegenera-
tion forward may be distinct from the initiating events. Final com-
mon pathways may also be more attractive targets for therapeutic 
intervention, as such agents are more likely to be effective across the 
gamut of ALS cases. Despite this, caution against overinterpreta-
tion of such secondary phenotypes is required. Indeed, attempts to 
replicate the effect of the KIFAP3 locus on survival have met with 
varied success74.
Lessons learned from ALS GWAS. The current state of play in ALS 
illustrates a recurring theme with GWAS methodology, namely that 
the sheer number of association tests performed on the same data set 
often leads to false-positive findings83. Although a variety of statisti-
cal tools can be employed to counter this, independent replication 
remains the gold standard. Such replication studies are greatly facili-
tated by the public availability of raw genotype data generated in ear-
lier GWAS. The release of such data allows other researchers around 
the world to access, reanalyze and combine it with their own GWAS, 
thereby increasing the power of their studies at no added cost.
By their very nature, GWAS of outbred populations require several 
thousand case and control samples to have sufficient power to identify 
risk loci. The Coriell ALS DNA Repository (http://www.coriell.org/), 
funded by the ALS Association, the Muscular Dystrophy Association 
and the National Institute of Neurological Disorders and Stroke, dis-
tributes well-phenotyped biological samples from ~2,000 case and 
~6,000 population control subjects84. The availability of this resource 
has invigorated the field by lowering the barriers for laboratories to 
engaging in genetic research.
The discovery of more and more causative genes confirms that 
ALS is not a monolithic clinical entity but rather consists of a group 
of diseases unified by the common theme of progressive motor neu-
ron degeneration. Such phenotypic and genetic heterogeneity con-
founds the ability of GWAS to identify associated regions. A standard 
approach to overcoming this obstacle has been to increase the size 
of case-control cohorts genotyped as part of GWAS. This approach 
Table 2 Other genes implicated in the pathogenesis of ALS
Gene Location Inheritance Predominant clinical syndromes Putative protein function
DCTN1 2p13 AD PMA; Perry syndrome Axonal transport
ALS2 2q33 AR Juvenile PLS; infantile HSP Vesicle trafficking
CHMP2B 3p11 AD Familial ALS; sporadic ALS; FTD Vesicle trafficking
FIG4 6q21 AD and AR CMT; familial ALS Vesicle trafficking
HNRNPA2B1 7p15 AD Multisystem proteinopathy; ALS RNA metabolism
ELP3 8p21 Undefined Sporadic ALS RNA metabolism
SETX 9q34 AD Juvenile ALS; ataxia with  
oculomotor apraxia
RNA metabolism
HNRNPA1 12q13 AD Multisystem proteinopathy; ALS RNA metabolism
ATXN2 12q24 Undefined Sporadic ALS; ataxia Endocytosis; RNA translation
ANG 14q11 AD Familial ALS; sporadic ALS Angiogenesis
SPG11 15q14 AR Juvenile ALS; HSP DNA damage repair
VAPB 20q13 AD PMA; FALS Vesicle trafficking
NEFH 22q12 AD Familial ALS; sporadic ALS Axonal transport
AD, autosomal dominant; AR, autosomal recessive; CMT, Charcot-Marie-Tooth disease; HSP, hereditary spastic  
paraplegia; PLS, primary lateral sclerosis; PMA, progressive muscular atrophy.
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has been successful in other neurodegenerative diseases, such as 
Parkinson’s disease and Alzheimer’s disease85,86, and lends credence 
to the view that similarly sized studies are likely to reveal more loci 
important to the pathogenesis of ALS.
A complementary technique has been to study conserved popula-
tions that display elevated rates of ALS. The reduced genetic hetero-
geneity found in such communities dramatically increases power to 
identify new genes responsible for disease. In Finland, our GWAS 
identified association signals on chromosome 9 (corresponding to 
the pathogenic C9ORF72 repeat expansion) and on chromosome 21 
(corresponding to the D90A allele of SOD1)75. These loci account 
for nearly all familial ALS cases in Finland and explain the high dis-
ease incidence observed in that population isolate. Our studies of 
Sardinian ALS patients have revealed two causative genes operating in 
that island population, namely the A382T-encoding allele of TARDBP 
and the C9ORF72 repeat expansion23,37. Similar efforts to exploit the 
Irish population have been less successful, but this may be due to the 
small size of the cohort or because this country does not have a higher 
rate of ALS than other European populations69,87.
Future directions for ALS GWAS. Older versions of genome-wide 
arrays selected common SNPs (minor allele frequency >5% in the gen-
eral population) to capture the maximum variation across the genome. 
This allowed the common disease/common variant hypothesis to be 
tested for a particular disease. In contrast, newer genotyping platforms 
(for example, the HumanExome Beadchip from Illumina) focus on 
rare variants (minor allele frequency <5%) located in the coding por-
tion of the genome. GWAS performed with these chips will test the 
hypothesis that a disease is caused by multiple rare variants. Given 
the relative rarity of ALS in the general population (incidence ~2 per 
100,000 in Europe), these new types of GWAS hold great promise.
Emerging themes in ALS genetics
De novo mutations. Spontaneously occurring mutations are a well-
known cause of neurological and non-neurological conditions, such 
as neurofibromatosis type 1 (ref. 88) and Hirschsprung’s disease89. 
Indeed, de novo mutations of FUS and SOD1 have been described in 
sporadic ALS cases90–92. Exome sequencing of parent–case offspring 
trios offers a new method to systematically search the genome for such 
variants. A recent publication from Gitler and colleagues highlights the 
potential power of this method and led to the identification and func-
tional characterization of mutations in the chromatin regulator SS18L1 
(also known as CREST) as possibly underlying ALS93. This publication 
represents an excellent first step, though it should be recognized that 
not all de novo variants are necessarily pathogenic. Validation of these 
‘hits’ in larger cohorts of familial and sporadic ALS cases is necessary 
to ensure that this new technique really flourishes.
Breakdown in classification of familial and sporadic ALS. The 
discovery that C9ORF72 is responsible for a sizeable proportion of 
sporadic ALS cases in populations of European ancestry has led to 
a fundamental shift in our understanding of the disease. Although 
categorization of ALS cases as familial or sporadic on the basis of 
family history retains some utility, it is clear that the underlying biol-
ogy is more nuanced and that such clinical classification should not 
be viewed in absolute terms94. This has profound implications for the 
clinical care and genetic testing in ALS95. It also lends credence to the 
notion that a genetic component underlies all of ALS and suggests that 
environmental and stochastic factors act as precipitating factors in 
genetically susceptible individuals, rather than being directly causa-
tive in their own right.
Oligogenic basis for ALS. An oligogenic basis has recently been pro-
posed in ALS families exhibiting Mendelian inheritance96. Under this 
model, mutations in two or more genes are required for an individual 
to develop disease. In some ways, this is reminiscent of the Knudson 
two-hit hypothesis implicated in carcinogenesis. While such events 
can occur in isolated populations, these are likely to be chance events 
driven by the high frequency of founder mutations in those regions97. 
A more parsimonious explanation for finding two ‘mutations’ in an 
ALS patient from an outbred population is that one of these variants 
is not truly pathogenic. In that regard, it is telling that many of the 
patients reported to carry two mutations in the Dutch population 
consisted of a mutation in an ALS gene and what may be a benign 
polymorphism in ANG96.
Nevertheless, one cannot a priori discount the possibility that ALS 
patients carry a primary genetic variant that drives susceptibility to 
disease and a secondary locus that influences age of symptom onset, 
symptom presentation and/or disease progression. Genome-wide 
data from several thousand patients across multiple countries will 
be required to resolve whether such genetic oligogenicity is relevant 
to ALS. The public availability of such large-scale data sets will allow 
future researchers to test for epistatic interactions among genes.
Extension of ALS phenotype and overlap between ALS and FTD. The 
more we learn about the genetics of ALS, the broader the associated 
phenotype becomes. For example, recognizing that ALS and FTD rep-
resent overlapping clinical syndromes has been a major step forward in 
our understanding, and this convergence has been strengthened by the 
discovery of C9ORF72 and other genes. In addition, VCP and SQSTM1 
show that the condition, at least in some cases, is not limited to the 
CNS and that diverse tissues such as muscle and bone may be affected. 
The discovery of mutations in HNRNPA2B1 and HNRNPA1 in families 
with ALS and in families with muscle-, bone- and neurodegeneration 
reinforces the notion that at least some forms of ALS are part of a more 
widespread disease process34. The term “multisystem proteinopathy” 
has been suggested to describe these diverse findings34.
Genes involved in other forms of motor neuron disease, such as 
hereditary spastic paraplegia and Charcot-Marie-Tooth disease, and 
even forms of neurodegeneration that are now regarded as quite 
distinct, may ultimately be linked to the ALS phenotype rubric. 
Expansions of the polyglutamine repeat in the coding region of 
ATXN2 cause a form of spinocerebellar ataxia (SCA2), and there 
appears to be clinical overlap between ALS and SCA2, with inter-
mediate-length expansions reported to increase the risk of ALS98,99. 
Intriguingly, ANG has been implicated in the pathogenesis of 
Parkinson’s disease100, although it is unclear why this locus was not 
detected in a previous GWAS of Parkinson’s disease involving 12,000 
cases and 20,000 controls86.
Conclusions and future directions
We have come a long way since the discovery of the first ALS gene 
20 years ago, and there is no doubt that genomics will continue to drive 
the research field forward. Analysis of increasingly large genetic data 
sets will improve our understanding of neurodegeneration. Although 
exome sequencing is in fashion, whole-genome sequencing will rise to 
prominence as costs continue to drop. Genome sequencing will yield 
even greater insight into the genetic architecture of ALS by providing 
a complete catalog of rare variants present in cases and allowing us 
to explore the role of noncoding and intergenic genetic variation in 
the pathogenesis of motor neuron degeneration. Combined with the 
promise of effective gene therapies, it is plausible that the next 20 years 
will see the mysteries of ALS simply melt away.
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